Go to content

Publications

497 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. GVS advice setmelanotide (Imcivree®)

    The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...

    Report | 08-07-2022

  2. GVS advice metreleptin (Myalepta®)

    The National Health Care Institute advises the Minister to include metreleptin (Myalepta®) in List 1B of the GVS. Metreleptin is ...

    Report | 08-07-2022

  3. GVS advice bempedoic acid (Nilemdo®) for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia

    The National Health Care Institute has completed its assessment whether bempedoic acid is interchangeable with another medicinal ...

    Report | 05-07-2022

  4. GVS advice cannabidiol (Epidyolex®) as adjuvant treatment for 2 epileptic disorders

    The National Health Care Institute advises the Minister only to include cannabidiol (Epidyolex®) on List 1B of the Medicine ...

    Report | 04-07-2022

  5. Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors

    The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...

    Report | 23-06-2022

  6. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®): extension of further conditions

    The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

    Report | 20-06-2022

  7. GVS advice bupropion in combination with naltrexone (Mysimba®)

    The National Health Care Institute advises the Minister to include bupropion in combination with naltrexone (Mysimba®) in the ...

    Report | 17-05-2022

  8. GVS advice GLP-1 receptor agonists extension further conditions

    The National Health Care Institute advises the Minister to extend the reimbursement conditions for dulaglutide, exenatide, ...

    Report | 16-05-2022

  9. GVS advice to not include pitolisant (Ozawade®)

    The National Health Care Institute has completed its assessment whether pitolisant (Ozawade®) can be included in the Medicine ...

    Report | 10-05-2022

  10. Package advice vitamin D

    The National Health Care Institute recommends that all colecalciferol-containing medicinal products and calcifediol be removed ...

    Report | 09-05-2022

Go to